ADMA BIOLOGICS, INC.

Tickers
ADMA
Headquarters
Not recorded
SEC CIK
0001368514
Website
Not recorded

Closing prices

Latest close, 11.75

Closing prices for ADMA249 stored closes for ADMA from 3 Nov 2025 to 29 Oct 2026. Lowest 7.60 on 2 Jun 2026, highest 20.38 on 11 Dec 2025, latest 11.75 on 29 Oct 2026.Close5.0010.0015.0020.0025.003 Nov 20251 May 202629 Oct 2026
249 stored closes, oldest first. End of day, not intraday.

Drugs

No drugs from this company are tracked yet.

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue124,395,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)37,822,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense6,014,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses33,832,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents136,020,000 USD At 30 Jun 2026 FY2026 Q210-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities0 USD At 31 Dec 2017 FY201710-K for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities276,002,000 USD At 30 Jun 2026 FY2026 Q210-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity408,208,000 USD At 30 Jun 2026 FY2026 Q210-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)223,984,680 shares At 31 Jul 2026 FY2026 Q210-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Apr 2026 to 30 Jun 2026 FY2026 Q2124,395,000 USD10-Q filed 5 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2026 to 31 Mar 2026 FY2026 Q1114,493,000 USD10-Q filed 6 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 FY2025510,173,000 USD10-K filed 25 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2025 Q3134,224,000 USD10-Q filed 5 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 FY2026 Q2121,984,000 USD10-Q filed 5 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 FY2026 Q1114,802,000 USD10-Q filed 6 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 FY2025426,454,000 USD10-K filed 25 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Sep 2024 FY2025 Q3119,839,000 USD10-Q filed 5 Nov 2025 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read

SEC filings

SEC filings from ADMA BIOLOGICS, INC., newest first
FormFiledWhat it coversDocument
10-QEvent 30 Jun 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 5 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-031445 (opens in a new tab)
8-K Current report (8-K)
  • Results of operations and financial condition (Item 2.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 5 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-031423 (opens in a new tab)
4Event 24 Jul 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 28 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-029923 (opens in a new tab)
4Event 16 Jul 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 17 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-028844 (opens in a new tab)
8-K Current report (8-K)
  • Shareholder vote results (Item 5.07)
View Current report (8-K) filed 2 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-023705 (opens in a new tab)
4Event 27 May 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 28 May 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-023127 (opens in a new tab)
4Event 12 May 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 14 May 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-021150 (opens in a new tab)
4Event 11 May 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 12 May 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-020855 (opens in a new tab)
10-QEvent 31 Mar 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 6 May 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-019336 (opens in a new tab)
8-K Current report (8-K)
  • Results of operations and financial condition (Item 2.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 6 May 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-019295 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
None in this period

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.